Displaying drugs 6651 - 6675 of 8282 in total
Elenbecestat
Elenbecestat is under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease).
Investigational
Matched Description: … under investigation in clinical trial NCT02956486 (A 24-Month Study to Evaluate the Efficacy and Safety of …
Brivoligide
Brivoligide is under investigation in clinical trial NCT04104919 (Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores).
Investigational
Matched Description: … Brivoligide is under investigation in clinical trial NCT04104919 (Study to Evaluate a Preop Dose of Brivoligide …
Birtamimab
Birtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
Investigational
Matched Description: … clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of …
Ordesekimab
Ordesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).
Investigational
Matched Description: … Ordesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of …
JLK-247
JLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of Sanfilippo Syndrome Type C or MPS IIIC.
Investigational
Matched Description: … adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of …
AGA2115
AGA2115 is a humanized bispecific antibody neutralizing both sclerostin and Dickkopf-1. Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.
Investigational
Matched Description: … Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis …
Skin-derived ABCB5-positive Mesenchymal Stem cells
Skin-derived ABCB5-positive Mesenchymal Stem cells are under investigation in clinical trial NCT04971161 (Allogeneic Abcb5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase Iib)).
Investigational
Matched Description: … clinical trial NCT04971161 (Allogeneic Abcb5-positive Dermal Mesenchymal Stromal Cells for Treatment of …
PAS-004
PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Investigational
Matched Description: … It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome. …
Socazolimab
Socazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-pd-l1 Antibody) in Patients With ES-SCLC).
Investigational
Matched Description: … Socazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide …
Plutavimab
Plutavimab is under investigation in clinical trial NCT04900428 (Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)).
Investigational
Matched Description: … Plutavimab is under investigation in clinical trial NCT04900428 (Study to Evaluate a Single Intranasal Dose of …
JNJ-39758979
JNJ-39758979 is under investigation in clinical trial NCT01480388 (A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate).
Investigational
Matched Description: … JNJ-39758979 is under investigation in clinical trial NCT01480388 (A Dose Range Finding Study of JNJ- …
Befiradol
Befiradol is under investigation in clinical trial NCT05148884 (Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia).
Investigational
Matched Description: … investigation in clinical trial NCT05148884 (Study to Assess the Safety, Tolerability and Preliminary Efficacy of …
KRN-330
Anti-a33 fully-human monoclonal antibody is under investigation in clinical trial NCT00838578 (Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer).
Investigational
Matched Description: … fully-human monoclonal antibody is under investigation in clinical trial NCT00838578 (Phase I/II Study of …
NUC-7738
NUC-7738 is under investigation in clinical trial NCT03829254 (A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma).
Investigational
Matched Description: … investigation in clinical trial NCT03829254 (A Safety, Pharmacokinetic and Clinical Activity Study of …
SGN-30
SGN-30 is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to on normal cells. SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase...
Investigational
Matched Description: … ) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of ... with chemotherapy for the treatment of relapsed Hodgkin lymphoma, front-line ALCL and pediatric ALCL ... We are collaborating with the National Cancer Institute (NCI) on three clinical trials of SGN-30 in combination …
Surotomycin
Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection. It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. Surotomycin has a fourfold greater in vitro potency than vancomycin against C. Difficile and other...
Investigational
Matched Description: … Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection ... acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of ... Difficile and other Gram-positive bacteria with minimal impact on the Gram-negative organisms of the …
Tengonermin
Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. This drug works by modifying the tumor microenvironment and increasing intratumoral chemotherapy penetration and T-cell infiltration. NGR-hTNF specifically targets angiogenic...
Investigational
Matched Description: … of NGR-hTNF to tumor vessels and the increase in its antiangiogenic activity. ... [A233265] It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis ... [A233270] A study also demonstrated that binding of the NGR-motif to CD13 determined both the homing …
Bimagrumab
Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.
Investigational
Matched Description: … Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal …
Nerve Growth Factor
Nerve Growth Factor has been used in trials studying the prevention and treatment of Mental Handicap, Alzheimer's Disease, Traumatic Brain Injury, Cerebral Palsy Children, and Delayed Speech Development, among others.
Investigational
Matched Description: … Nerve Growth Factor has been used in trials studying the prevention and treatment of Mental Handicap, …
Emrusolmin
Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology.
Experimental
Matched Description: … spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of …
Rovafovir etalafenamide
Rovafovir etalafenamide is under investigation in clinical trial NCT03472326 (Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen).
Investigational
Matched Description: … Rovafovir etalafenamide is under investigation in clinical trial NCT03472326 (Efficacy of GS-9131 Functional …
Teprasiran
Teprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery).
Investigational
Matched Description: … Teprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major …
RAPA-501-Allo
RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed ex vivo in a process that involves de-differentiation and re-differentiation.
Investigational
Matched Description: … RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed …
TERN-101
TERN-101 is under investigation in clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH)).
Investigational
Matched Description: … clinical trial NCT04328077 (LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of …
Gontivimab
Gontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection).
Investigational
Matched Description: … Gontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult …
Displaying drugs 6651 - 6675 of 8282 in total